In recent decades, the prevalence of diabetes in China has increased by 4 times, and now about 110 million adults are suffering diabetes, while exceeding the number of patients in any other country in the world. Patients with diabetes need lifelong medication to control the condition, so it will be a big burden for patients and their families with difficult economic conditions; also, it is a major social problem that our government needs to face.

"2017 Aisuixinda - Diabetes Public Welfare Assistance Program", initiated by China Primary Health Care Foundation (hereinafter referred as "Primary Health Care Foundation") and donated by 3SBio, was launched in Beijing on February 14, 2017, and it was the first patient assistance program in the field of diabetes prevention and control in China, with an aim to make timely and effective treatment available to more patients with type 2 diabetes, to relieve the economic burden of patients, to improve the life quality of patients and to enhance patients' confidence in disease treatment.It is estimated that the program will be carried out in 39 cities of China in 2017, covering more than 6,000 patients and giving out 20,000 doses of Exenatide Injection (an assisted drug).

2017 Aisuixinda - Diabetes Public Welfare Assistance Program will freely provide Exenatide Injection donated by 3SBio for patients with type 2 diabetes qualified for the conditions of the program, and program condition is that patients eligible for getting free Exenatide Injection must be with basic living allowance or low income. The program was officially started on February 14, 2017 and gradually carried out in 39 cities (note: Fuzhou, Nanning, Nantong and Xinxiang were included in aid scope, and the original aid scope was 35 cities); the Official Website（http://byettapap.ilvzhou.com）and Hotline (4000-186-037) of the program were officially updated and launched on February 14.